Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.03 USD | +3.89% | +3.72% | -22.83% |
May. 31 | Ionis Reports 'Positive Results' From Studies of Investigational Treatment for Hereditary Angioedema | MT |
May. 31 | Transcript : Ionis Pharmaceuticals, Inc. - Special Call |
Financials (USD)
Sales 2024 * | 597M | Sales 2025 * | 767M | Capitalization | 5.48B |
---|---|---|---|---|---|
Net income 2024 * | -576M | Net income 2025 * | -523M | EV / Sales 2024 * | 8.23 x |
Net cash position 2024 * | 567M | Net Debt 2025 * | 318M | EV / Sales 2025 * | 7.56 x |
P/E ratio 2024 * |
-9.86
x | P/E ratio 2025 * |
-11.2
x | Employees | 927 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.13% |
Latest transcript on Ionis Pharmaceuticals, Inc.
1 day | +2.79% | ||
1 week | +0.78% | ||
1 month | -12.81% | ||
3 months | -17.36% | ||
6 months | -27.23% | ||
Current year | -25.74% |
Managers | Title | Age | Since |
---|---|---|---|
D. Walke
FOU | Founder | 58 | 12-06-30 |
Brett Monia
FOU | Founder | 62 | 89-01-09 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 62 | 00-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Loscalzo
CHM | Chairman | 72 | 14-02-02 |
Brett Monia
FOU | Founder | 62 | 89-01-09 |
Joan Herman
BRD | Director/Board Member | 70 | 19-06-09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.89% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 39.04 | +3.91% | 147 569 |
24-05-31 | 37.57 | +2.79% | 1,396,671 |
24-05-30 | 36.55 | +0.27% | 891,459 |
24-05-29 | 36.45 | -3.16% | 1,103,662 |
24-05-28 | 37.64 | +0.97% | 575,806 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.74% | 5.48B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- IONS Stock